1.Clinical characteristics and efficacy of second primary malignancies in hypopharyngeal carcinoma: an analysis of 216 real-world cases
Xi LUO ; Runye WU ; Shaoyan LIU ; Xiaolei WANG ; Xiaoguang NI ; Ye ZHANG ; Xiaodong HUANG ; Kai WANG ; Xuesong CHEN ; Jingbo WANG ; Jianghu ZHANG ; Yuan QU ; Jingwei LUO ; Junlin YI
Chinese Journal of Radiation Oncology 2023;32(3):194-200
Objective:To evaluate the incidence, clinical characteristics and prognosis of second primary malignancies (SPMs) among patients with hypopharyngeal carcinoma (HPC) in real-world analysis.Methods:A total of 594 HPC patients admitted to Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from 2010 to 2018 were retrospectively analyzed.The incidence and clinical characteristics of HPC patients complicated with SPMs were analyzed. Clinical efficacy was compared among different groups.Results:With a median follow-up time of 66.9 months, SPMs were present in 36.4% (216/594) of HPC patients: 22.2% (132/594) were synchronous and 14.1% (84/594) were metachronous. The upper aerodigestive tract was the most common involved region. Compared with patients without SPMs, patients with synchronous and metachronous carcinoma in situ had similar 5-year overall survival (OS) of 42.2% vs. 44.5% ( P=0.958) and 62.2% vs. 44.5% ( P=0.240), respectively. Patients with synchronous invasive SPMs had a worse 5-year OS of 27.2% vs. 44.5% in their counterparts without SPMs ( P=0.001). Patients with metachronous invasive SPMs had similar 5-year OS of 50.2% vs. 44.5% in their counterparts without SPMs ( P=0.587). SPMs accounted for 42.5% of total death in metachronous invasive SPMs group. Conclusions:Patients with HPC have a high probability of developing SPMs. Moreover, the incidence of complicated with esophageal/gastric carcinoma in situ or metachronous SPMs exerts no effect on prognosis, while the occurrence of synchronous SPMs significantly affectes the prognosis of patients. However, the incidence of SPMs is still one of the main death causes in metachronous invasive SPMs group.
2.Clinicopathological characteristics between papillary thyroid microcarcinoma and papillary thyroid carcinoma of diameter≥2 cm
Yijun WANG ; Meiqi NI ; Xiaoguang SHI ; Weiping TENG
Chinese Journal of Endocrinology and Metabolism 2021;37(6):548-553
Objective:To compare the differences in clinicopathological characteristics between papillary thyroid microcarcinoma (PTMC) and papillary thyroid carcinoma (PTC) with a diameter≥2 cm.Methods:Clinicopathological and follow-up information of 1 404 PTC cases with diameter≤9 cm who received surgery and were confirmed pathologically from January 2010 to May 2017 in the First Hospital of China Medical University were analyzed retrospectively. All cases were divided into PTMC group and diameter ≥2 cm PTC group according to tumor diameter. The diameter of ≥2 cm PTC group was further categorized into two subgroups with 4 cm as the boundary. Clinical and pathological characteristics were analyzed. Meanwhile, risk factors that affected lymph node metastasis and postoperative recurrence of tumor were analyzed as well.Results:(1) A total of 1 404 eligible patients were included, consisting of 1 001 cases (71.3%) of PTMC and 403 cases (28.7%) of PTC of diameter≥2 cm with a median follow-up time of 43.00 (8.00-94.00) months. There were statistical differences in gender, age, serum thyroid stimulating hormone (TSH) level, bilobe, multifocality, cervical lymph node metastasis, extrathyroidal extension, body mass index, postoperative death, postoperative recurrence, and 131I treatment rate between two groups. Age, serum TSH level, bilobe, multifocality, cervical lymph node metastasis, extrathyroidal extension, postoperative recurrence, and 131I treatment rate were found statistically different among the PTMC group, 2 cm≤diameter≤4 cm PTC group, and 4 cm
3.Correlation of hENT1 protein expression with curative effect and prognosis of gemcitabine in pancreatic cancer
Yi ZHANG ; Xiaodan YANG ; Xiaoguang WANG ; Bin WU ; Quanfa NI ; Zhengwei SONG ; Jianguo FEI
Chinese Journal of Pancreatology 2019;19(2):103-106
Objectives To investigate the relationship between the expression of hENT1 protein in pancreatic cancer and the efficacy,adverse reactions and prognosis of gemcitabine.Methods The tissues of 83 patients with pancreatic cancer diagnosed in Department of Hepatobiliary and Pancreatic Surgery of Jiaxing Second Hospital and Jiaxing City Hospital of Traditional Chinese Medicine from June 2013 to January 2016 were collected by endoscopic fine needle aspiration biopsy.The expression of hENT1 protein was detected by immunohistochemistry,which was divided into hENT1 low expression group and high expression group.According to the curative effect of chemotherapy,it was divided into gemcitabine effective group and drug resistance group.The clinicopathological parameters,adverse reaction rate,median survival,and progressionfree survival (PFS) were compared between the two groups.Results Of the 83 pancreatic cancer tissues,37 (44.6%) had high expression of hENT1 and 46 (55.4%) had low expression.There were no significant correlations of the efficacy of gemcitabine chemotherapy with gender,age,clinical symptoms,primary tumor location,tumor size,TNM staging,CA19-9 level,CEA level,presence or absence of liver metastasis,but gemcitabine resistance rate in high expression group was significantly higher than the low expression group (78.1% vs 50.0%),and the difference was statistically significant (P =0.010).Both groups were able to tolerate adverse reactions of gemcitabine chemotherapy and no chemotherapy-related death was observed,but the incidence of leucopenia and thrombocytopenia in hENT1 low expression group was significantly higher than those in bENT1 protein high expression group (63.0% vs 21.6%,47.8% vs 16.2%),the differences was statistically significant (all P < 0.05).The median survival and 1-year PFS of hENT1 protein low expression group were significantly lower than those of high expression group (11 months vs 15 months,19.4% vs 50%),and the differences were statistically significant (P <0.05).Conclusions Decreased hENT1 protein expression in pancreatic cancer tissue could reduce the efficacy of gemcitabine chemotherapy,increasing the incidence of leucopenia and thrombocytopenia.
5.Relationships between peripheral circulating tumor cells in patients with gallbladder carcinoma detected by a novel nano microfluidic chip with clinicopathology and prognosis
Xiaoguang WANG ; Bin WU ; Quanfa NI ; Lifeng QI ; Jianguo FEI ; Zhengxiang ZHONG
Chinese Journal of Hepatobiliary Surgery 2018;24(5):321-324
Objective To establish a novel method using a nano microfluidic chip to detect circulating tumor cells (CTCs) in peripheral blood in gallbladder carcinoma,and to study the relationship between CTCs with clinicopathology and prognosis in these patients.Methods The peripheral blood samples of 51 patients with gallbladder carcinoma were collected from June 2014 to January 2017.The CTCs from peripheral blood samples were detected by a novel nano microfluidic chip.This study aimed to study the correlation between CTCs with the clinical and pathological features.The significance of CTCs on prognosis in patients with gallbladder carcinoma was also analyzed.Results The positive rate of CTCs in the peripheral blood of gallbladder carcinoma patients was 43.1% (22/51).There were significant correlations between CTCs with liver metastasis (P < 0.05) and Nevin staging (P < 0.05).The 1-and 2-year overall survival (OS) in patients with CTCs were 70.7% and 35.3%,and the 1-and 2-year OS in patients without CTCs were 92.0% and 56.1%.There was a significant difference in the 2-year OS (P < 0.05) but no significant difference in the 1-year OS between the 2 groups of patients (P > 0.05).Conclusions Peripheral blood CTCs in patients with gallbladder carcinoma were efficaciously detected by a novel nano microfluidic chip.Peripheral blood CTCs was closely related to the Nevin staging and liver metastasis.CTCs could serve as a potential prognostic indicator in patients with gallbladder carcinoma.
6.Expert Consensus for Image-guided Radiofrequency Ablation of Pulmonary Tumors (2018 Version).
Baodong LIU ; Xin YE ; Weijun FAN ; Xiaoguang LI ; Weijian FENG ; Qiang LU ; Yu MAO ; Zhengyu LIN ; Lu LI ; Yiping ZHUANG ; Xudong NI ; Jialin SHEN ; Yili FU ; Jianjun HAN ; Chenrui LI ; Chen LIU ; Wuwei YANG ; Zhiyong SU ; Zhiyuan WU ; Lei LIU
Chinese Journal of Lung Cancer 2018;21(2):76-88
8.The applied analysis of amputation of secondary pedicles of the spleen in laparoscopic splenectomy in hypersplenism caused by the schistosoma cirrhosis
Xiaodan YANG ; Zhengwei SONG ; Xiaoguang WANG ; Quanfa NI ; Hongbo QIN ; Wei YU ; Jianguo FEI
Chinese Journal of Postgraduates of Medicine 2017;40(6):539-541
Objective To investigate the feasibility, efficacy, safety and economy of secondary splenic pedicle trisection method in removing schistosoma cirrhosis caused the splenic function. Methods Thirty patients receiving spleen secondary structure amputation between July 2014 and September 2016 were analyzed. Results Laparoscopic splenectomy with secondary splenic pedicle transaction was successfully performed in 28 patients, whereas two Endo-GIAs were used in 2 patients. The average of operation time was (80 ± 20) min, and operative blood loss was (320 ± 10) ml. The drainage of the splenic fossa was removed (3- 4) days after operation.Postoperative hospital stay was (10.8 ± 1.2) days after operaions. No massive hemorrhage, pancreatic leakage, secondary infection, serious complications such as abscess under diaphragm and recent complication such as infection of incision occurred postoperatively. Platelet of all patients recovered in 4 days postoperatively, and patients with platelet>400 × 109/L was given oral aspirin enteric-coated metformin hydrochloride. All patients were followed up for 6 months postoperatively, and no intestinal obstruction, portal vein thrombosis and other long-term complications occurred in all patients. Conclusions The amputation of secondary structures of the spleen in laparoscopic splenectomy to remove schistosoma cirrhosis caused the splenic function is safe. It could shorten the length of hospital stay and reduce the medical cost. It is a valuable method for clinical promotion.
9. Risk factors and survival analysis for synchronous esophageal carcinoma in patients with hypopharyngeal carcinoma
Qingqing ZHANG ; Xiaoguang NI ; Shun HE ; Yueming ZHANG ; Lizhou DOU ; Shaoqing LAI ; Guiqi WANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2017;52(10):749-754
Objective:
To investigate the risk factors and survival status of hypopharyngeal carcinoma with synchronous second primary carcinoma of the esophagus.
Methods:
One hundred and sixty patients with newly diagnosed hypopharyngeal carcinoma from January 2009 to December 2012 were retrospectively reviewed. The clinical data, tumor-related information and follow-up results were collected and analyzed.
Results:
Forty-three synchronous esophageal carcinomas (27%) were detected in 160 patients with hypopharyngeal carcinoma, and most patients (72%) were at an early stage. On univariate analysis, the median age of less than 55 years old (χ2=4.525,

Result Analysis
Print
Save
E-mail